GTx Nixes Toremifene After Ipsen Terminates Partnership
By Marie Powers
Thursday, March 3, 2011
GTx Inc. plans to walk away from toremifene after the company "mutually agreed to terminate" its collaboration with Ipsen Group SA to develop and commercialize the drug, GTx CEO Mitchell Steiner told BioWorld Today.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.